| Routes of|
|Part of a series on the|
QazCovid-in, commercially known as QazVac,is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.
The vaccine can be stored at standard refrigeration temperatures (2°C-8°C) and is a two-dose régime with the doses administered twenty-one days apart.
The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.
Beginning in June 2021, the vaccine is slatedto be packaged in large bulk to be bottled in Turkey by a major Turkish company. This will allow for a production capacity of 500,000-600,000 doses per month. The contract is still being negotiated, despite earlier claims suggesting that the deal had already been finalized.
In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.
In September 2020, QazVac started in Phase I/II clinical trials.
In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021.It is unclear when the first preliminary results will be published.
The administration of the vaccine for the general population began at the end of April 2021.The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".
In September 2021, a study was published to EClincicalMedicine, published by The Lancet. The study’s finidings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.”
The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.[ citation needed ] In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company is based in Haidian District, Beijing in China. The company is listed on the NASDAQ but the exchange halted Sinovac's trading in February 2019 due to a proxy fight.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.
Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.
CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to BBIBP-CorV and Covaxin, other inactivated-virus COVID-19 vaccines. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.
Valneva COVID-19 vaccine, also known as the VLA2001 and VLA2101, is a COVID-19 vaccine candidate developed by French biotechnology company Valneva SE in collaboration with American company Dynavax Technologies.
ZF2001, trade-named ZIFIVAX or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.
EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants. The interim results of the Phase III study are expected to be announced in late 2021 or early 2022. According to the vaccine developers, the peptides and the viral part of the chimeric protein should immunize people who received this vaccine against SARS-CoV-2 and trigger the production of protective antibodies. However, some experts in the field have expressed concerns about the selection of peptides for use as vaccine antigens. In addition, there are also serious concerns about the vaccine immunogenicity data, which have fueled independent civic research efforts and criticism by some experts. Meanwhile, the EpiVacCorona has received vaccine emergency authorization in a form of government registration in Russia and is available for vaccination outside the clinical trials. The vaccine delivered via intramuscular route and aluminum hydroxide serves as an immunological adjuvant.
The CureVac COVID-19 vaccine is a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy.
Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.
TURKOVAC is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.
NDV-HXP-S is a COVID-19 vaccine candidate developed by a team led by Jason McLellan at the University of Texas at Austin, together with groups from the Icahn School of Medicine at Mount Sinai and the National Institute of Allergy and Infectious Diseases Vaccine Research Center, based on an improved spike protein central to its resilience and efficacy.
Razi Cov Pars is a COVID-19 vaccine candidate developed by the Iranian Razi Vaccine and Serum Research Institute.
Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.
COVID-19 vaccination in Kazakhstan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVI-VAC is a COVID-19 vaccine being developed by Codagenix, Inc. It is currently in Phase I clinical trials, involving 48 participants which runs from December 2020 to June 2021.
FAKHRAVAC is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It's the third Iranian COVID-19 vaccine reaching clinical trials. It's currently in phase III. It has received emergency use authorization in Iran on 9 September 2021.
ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.
COVID-19 vaccine clinical research is the clinical research on COVID-19 vaccines, including their efficacy, effectiveness and safety. There are 22 vaccines authorized for use by national governments, with six vaccines being approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; and five of them are in Phase IV. 204 vaccines under clinical trials that have not yet been authorized. There are also nine clinical trials on heterologous vaccination courses.
|Scholia has a profile for QazCovid-in (Q99518269).|